Profile

embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe.

Visit www.embecta.com

Key Products

embecta is the world’s leading producer of insulin injection devices, manufacturing approximately 8 billion insulin syringes and pen needles each year that are used by 30 million people in over 100 countries.

To know more about their products, click here.

Honors and Recognitions

Key Executives

• Devdatt (Dev) Kurdikar, President and Chief Executive Officer


• Ginny Blocki, SVP, Global Marketing & Project Management


• Tom Blount, SVP, President, North America


• Jean Casner, SVP, Chief Human Resources Officer


• Shaun Curtis, SVP, Global Manufacturing & Supply Chain


• Jake Elguicze, SVP, Chief Financial Officer


• Jeff Mann, SVP, General Counsel & Head of Business Development


• Slobodan Radumilo, SVP, President, International


• Colleen Riley, SVP, Chief Technology Officer

To view their executive page, click here.

Board Members

• David F. Melcher, Non-Executive Chairman of the Board


• David J. Albritton, Director


• Carrie L. Anderson, Director


• Robert (Bob) J. Hombach, Director


• Devdatt (Dev) Kurdikar, Director


• Milton M. Morris, Ph.D. , Director


• Claire Pomeroy, Director


• Karen N. Prange, Director


• Christopher R. Reidy, Director

To view their executive page, click here.

News and Press Releases

• Jan 2024: embecta Announces FDA 510(k) Submission for Insulin Patch Pump (Read).


• Oct 2023: embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell (Read).


• May 2023: embecta and Tidepool partner to develop automated insulin delivery system for people with Type 2 diabetes (Read).


• Jan 2023: embecta opens new global headquarters in Parsippany, N.J. (Read).

To view their full press release, click here.

Competitors

• Novo Nordisk


• Medtronic


• Insulet


• Ypsomed


• Tandem.

Corporate Responsibility

As a newly independent organization, embecta has dedicated significant time and resources to social responsibility aligned with its core values. A major portion of its outreach comes through strong partnerships with over 20 diabetes-centered nonprofit or NGO organizations. Notably, embecta supports the Diabetes Scholars program by Beyond Type 1, which provides scholarships to high school students with type 1 diabetes to support their career aspirations. The company also backs the Diabetes Foundation’s initiatives to offer free education and support programs, helping individuals with prediabetes or diabetes gain the knowledge and tools to reduce the risk of developing diabetes or avoid long-term complications.

Dr. Henry Anhalt, embecta’s Chief Medical Officer, has long been a supporter and board member of Camp Nejeda, a New Jersey-based camp dedicated to enhancing the lives of children with type 1 diabetes and their families. Reflecting embecta’s patient-centric culture, employees across the organization regularly volunteer their time and efforts to support Camp Nejeda throughout the year.

On a global scale, embecta is committed to reducing waste through a recycling program, source reduction, waste minimization, and alternative disposal methods such as beneficial reuse. At its Suzhou, China site, embecta has installed photovoltaic power generation capacity, expected to generate 15% of the site’s annual energy use and reduce carbon dioxide emissions by about 771 tons annually. All embecta manufacturing sites are ISO 14001 certified, actively monitoring and striving to minimize impacts related to waste, energy consumption, and emissions.